NCT02353819View on ClinicalTrials.gov

Stereotactic Ablative Radiotherapy (SABR) of Pelvis and Prostate Targets For High Risk Prostate Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

January 31, 2030

Study Completion Date

December 31, 2030

Conditions
Prostate Cancer
Interventions
RADIATION

Stereotactic Ablative Radiotherapy

SABR x5 fractions CBCT based image-guidance prior to each fraction: localize based on prostate/seeds positions SCORE system

Trial Locations (1)

75239

University of Texas Southwestern Medical Center, Dallas

All Listed Sponsors
collaborator

National Institute for Biomedical Imaging and Bioengineering (NIBIB)

NIH

lead

University of Texas Southwestern Medical Center

OTHER

NCT02353819 - Stereotactic Ablative Radiotherapy (SABR) of Pelvis and Prostate Targets For High Risk Prostate Cancer | Biotech Hunter | Biotech Hunter